Don’t know much about Tesla MRI… Don’t know if the prostate cancer I got will make me die…
October 26, 2016 by John McHugh M.D.
I’m reading a book about Edison suing Westinghouse in the late nineteenth century and the development of alternating current. The Serbian who “conquered” alternating current was a idiosyncratic man named Nikola Tesla. It is very interesting however I am in love with the nineteenth century and the men and women of history of that era. Think Twain, Edwin Booth, Henry James, Grant, Kipling, Osler, Roebling, Carnegie, Frick, etc and etc.
So about the study that follows and there are a lot like them. The advent of the MRI for the prostate and what does it mean, does it help, is it really that much better than systematic ultrasound guided biopsies considering the cost and time element.
In a time of all the talk of cost, why is there not more condemnation of the cost of the MRI and the interpretation of it by the radiologist by our “experts.”
Anyway here is the article. Keep in mind I have done thousands of prostate biopsies in my career and the expense of the procedure, the ultrasound, the materials used and what is paid to me for doing is less expensive than an MRI alone. Where is the outrage?
Poor little ole PSA. The Rodney Dangerfield of Medicine. Are the letters MRI more sexually appealing than the letters PSA. Oh by the way…why do you order a MRI in the first place? You guessed it…an elevated PSA…that dirty rascal keeps popping his knarly little ole head…don’t he?
Feel free to opine…if you are well versed in the MRI movement, the benefits, the cost, and why it should be the only study done on men suspected of prostate cancer please…comment. I truly want to be enlightened. Predict the future.
Prostate MRI in the Prebiopsy Setting
Urology – June 15, 2016 – Vol. 34 – No. 3
Prostate MRI in the prebiopsy setting may help identify Gleason 7 and higher cancers.
Article Reviewed: Prebiopsy MRI and MRI-Ultrasound Fusion-Targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. Mendhiratta N, Meng X, et al: Urology; 2015;86 (December): 1192-1198.
Background: Prostate MRI has seen an explosion of use over the past 5 years. The perceived benefit of prostate MRI is in the identification of high-grade disease and thereby decreasing the overdetection of clinically insignificant prostate cancers.
Participants: Patients presenting to a single institution with elevated prostate-specific antigen (PSA) levels.
Methods: Patients underwent multiparametric prostate MRI with a 3 Tesla unit. Prostate lesions were scored on a scale of 1 to 5, with 5 being very high probability of cancer. Patients with target lesions underwent targeted biopsy with a standard 12-core template biopsy. Patients with a normal MRI were not included in the study, as targeted biopsy could not be performed.
Results: 352 patients were included in the study. Prostate cancer was identified in 207 men. Cancer detection rate was higher in the standard template group (49.2%) than in the targeted biopsy group (43.5%). However, targeted biopsies detected more Gleason 7 or greater disease (88.6%) compared to the standard template (77.3%). Higher volumes of clinically insignificant prostate cancers were detected by standard biopsies. Using suspicion level of 4 and 5, 85.9% of patients were found to have prostate cancer, with 69.1% having Gleason 7 or higher. Using suspicion level 4 and 5, sensitivity, specificity, and negative and positive predictive value were 78.0%, 81.6%, 87.6% and 69.1%, respectively, for finding Gleason 7 or greater disease.
Conclusions: For men with elevated PSA levels, multiparametric MRI is a valuable tool in the prebiopsy setting for detecting clinically significant disease.
Reviewer’s Comments: The authors present compelling data for the addition of MRI in the prebiopsy setting for patients with elevated PSA. What is not included in the study are the data for those patients with negative prostate MRI. In addition, MRI is an expensive imaging modality. Does improved detection of Gleason 7 prostate cancers justify the cost on a population level?(Reviewer–Michael Poch, MD).